Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pentoxifylline for Prevention of Post-ERCP Pancreatitis
NCT02992678Phase 1Unknown
- Sponsor
- The First Affiliated Hospital of USTC
- Start
- Dec 2016
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP) comparing Pentoxifylline with Placebo (2 arms). Primary endpoint: Acute Pancreatitis at 24 hours. Status: unknown.
02
Drugs
pentoxifylline
03
Conditions
post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP)
Beyond the preview
Go deeper on NCT02992678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02992678.